Drugs that contain Linaclotide

1. Drug name - LINZESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 4 months from now)

US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 4 months from now)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 4 months from now)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 4 months from now)

US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(3 years from now)

CN101010335A ALLERGAN The Method And Combination For Curing The Gastrointestinal Disease
Sep, 2011

(11 years ago)

CN102020704A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Apr, 2013

(9 years ago)

CN100589839C ALLERGAN Polypeptide And A Pharmaceutical Composition Comprising The Polypeptide
Jan, 2024

(1 year, 4 months from now)

CN1795007A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

CN101787073B ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

CN101787073A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

IN200503394P1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

IN237521B ALLERGAN A Purified Peptide Which Activates The Guanylate Cyclase C Receptor For Use In Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

EP1911763B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

EP1911763A2 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

EP1911763A3 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 4 months from now)

EP2088154B1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Mar, 2025

(2 years from now)

EP2088154A1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Mar, 2025

(2 years from now)

EP1594517A4 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP1594517A2 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP2246360A1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP2246360B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

EP1594517B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Nov, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders Jan, 2024

(1 year, 4 months from now)

US8933030 ALLERGAN Treatments for gastrointestinal disorders Feb, 2031

(8 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide Aug, 2031

(8 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide Aug, 2031

(8 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide Oct, 2031

(9 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration Oct, 2031

(9 years from now)

US9708371 ALLERGAN Treatments for gastrointestinal disorders Aug, 2033

(10 years from now)

Treatment: Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
72MCG CAPSULE;ORAL Prescription
145MCG CAPSULE;ORAL Prescription
290MCG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.